David H. Kirn

David H. Kirn is a renowned medical professional and biotechnology entrepreneur, best known for his contributions to the field of oncolytic virotherapy. He is the co-founder and CEO of 4D Molecular Therapeutics, a company that specializes in the development of targeted and personalized gene therapy products.

Early Life and Education[edit | edit source]

David H. Kirn was born and raised in the United States. He completed his undergraduate studies at Stanford University, where he developed a keen interest in biology and medicine. He then pursued his medical degree from the University of California, San Francisco (UCSF), one of the leading medical schools in the country.

Career[edit | edit source]

After completing his medical degree, Kirn worked in various medical and research institutions, gaining valuable experience in the field of oncology. His interest in virology and its potential applications in cancer treatment led him to establish his own biotechnology company, 4D Molecular Therapeutics.

At 4D Molecular Therapeutics, Kirn and his team are focused on developing targeted gene therapy products for the treatment of various diseases, including cancer, cardiovascular diseases, and neurodegenerative diseases. Their work involves the use of adenoviruses as vectors to deliver therapeutic genes to specific cells in the body.

Contributions to Oncolytic Virotherapy[edit | edit source]

Kirn's most significant contribution to the field of medicine is his work on oncolytic virotherapy. This innovative treatment approach involves the use of viruses to selectively kill cancer cells while leaving healthy cells unharmed. Kirn's research in this area has led to the development of several promising oncolytic viruses, which are currently being tested in clinical trials.

Recognition[edit | edit source]

In recognition of his contributions to the field of medicine and biotechnology, Kirn has received numerous awards and honors. He is a member of several prestigious medical and scientific societies, and his work has been published in top-tier scientific journals.